Suppr超能文献

镰状细胞病造血细胞移植后疼痛危象的发生率及危险因素。

Incidence and risk factors of pain crisis after hematopoietic cell transplantation for sickle cell disease.

机构信息

Section of Pediatric Hematology-Oncology and Stem Cell Transplantation, Yale School of Medicine, New Haven, CT.

Yale Center for Analytical Sciences, Yale School of Public Health, New Haven, CT.

出版信息

Blood Adv. 2024 Apr 23;8(8):1908-1919. doi: 10.1182/bloodadvances.2023010749.

Abstract

Vaso-occlusive episodes (VOC) or pain crises are the most common indications for hematopoietic cell transplantation (HCT) for sickle cell disease (SCD). Elimination of pain crisis after HCT is an important patient-centered outcome and may improve understanding of the natural history of pain syndromes in SCD. We examined deidentified records of 763 patients followed-up for a median of 36.7 months (range, 0.3-168.6 months), with 69.6% patient's age <18 years at HCT, 83.3% patient's Karnofsky-Lansky performance score (KPS) ≥90, overall survival 92.9%, event-free survival 72.4%, graft failure (GF) 22.4%, AGVHD 21.4%, CGVHD 27%, and pain crisis 8.65%. On unadjusted logistic regression, increased risk of pain crisis after HCT was observed in patient's aged >10 years at HCT (range, 11-17 years; OR, 9.43; 95% CI, 3.20-27.79; P < .0001), in age ≥18 years (OR, 16.62; 95% CI, 5.85-47.16; P < .0001), in those with history of pain crisis 2 years before HCT (OR, 13.16; 95% CI, 4.08-42.42; P < .0001), alternate donors (haploidentical [OR, 4.80; 95% CI, 2.48-9.31; P < .0001], unrelated matched [OR, 2.71; 95% CI, 1.23-5.97; P = .0132], and mismatched unrelated [OR, 3.19; 95% CI, 1.44-7.05; P = .0041], and those with GF (n = 41 [5.37%]; OR, 7.15; 95% CI, 4.20-12.18; P < .0001). Pain crisis was less frequent with KPS of ≥90 (OR, 0.31; 95% CI, 0.18-0.55; P < .0001). Multivariable logistic regression models confirmed age at HCT, KPS, graft type, donor type, history of VOC 2 years before HCT, and GF as independent predictors of pain crisis after HCT and generated predictive models and nomograms for pain crisis after HCT for SCD, which can support shared decision making.

摘要

血管阻塞性发作(VOC)或疼痛危象是镰状细胞病(SCD)患者接受造血细胞移植(HCT)的最常见指征。HCT 后消除疼痛危象是一个重要的以患者为中心的结果,可能有助于了解 SCD 疼痛综合征的自然史。我们检查了 763 名接受中位随访 36.7 个月(范围,0.3-168.6 个月)患者的匿名记录,其中 69.6%的患者在 HCT 时年龄<18 岁,83.3%的患者 Karnofsky-Lansky 表现评分(KPS)≥90,总生存率为 92.9%,无事件生存率为 72.4%,移植物失败(GF)为 22.4%,急性移植物抗宿主病(AGVHD)为 21.4%,慢性移植物抗宿主病(CGVHD)为 27%,疼痛危象为 8.65%。在未调整的逻辑回归中,我们观察到 HCT 后疼痛危象的风险增加与患者在 HCT 时年龄>10 岁(范围,11-17 岁;OR,9.43;95%CI,3.20-27.79;P<.0001)、年龄≥18 岁(OR,16.62;95%CI,5.85-47.16;P<.0001)、HCT 前 2 年有疼痛危象史(OR,13.16;95%CI,4.08-42.42;P<.0001)、使用非血缘供者(单倍体相合[OR,4.80;95%CI,2.48-9.31;P<.0001]、无关匹配供者[OR,2.71;95%CI,1.23-5.97;P=0.0132]和不匹配的无关供者[OR,3.19;95%CI,1.44-7.05;P=0.0041]、以及有 GF(n=41 [5.37%])的患者(OR,7.15;95%CI,4.20-12.18;P<.0001)有关。KPS≥90 的患者疼痛危象发生率较低(OR,0.31;95%CI,0.18-0.55;P<.0001)。多变量逻辑回归模型证实了 HCT 时的年龄、KPS、移植物类型、供者类型、HCT 前 2 年的 VOC 史和 GF 是 HCT 后疼痛危象的独立预测因素,并生成了 SCD 患者 HCT 后疼痛危象的预测模型和列线图,可支持共同决策。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/43cd/11021890/dfc7d21c445c/BLOODA_ADV-2023-010749-ga1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验